Literature DB >> 19092437

Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Samuel M Moskowitz1, James F Chmiel, Darci L Sternen, Edith Cheng, Ronald L Gibson, Susan G Marshall, Garry R Cutting.   

Abstract

Cystic fibrosis transmembrane conductance regulator-related disorders encompass a disease spectrum from focal male reproductive tract involvement in congenital absence of the vas deferens to multiorgan involvement in classic cystic fibrosis. The reproductive, gastrointestinal, and exocrine manifestations of cystic fibrosis transmembrane conductance regulator deficiency are correlated with CFTR genotype, whereas the respiratory manifestations that are the main cause of morbidity and mortality in cystic fibrosis are less predictable. Molecular genetic testing of CFTR has led to new diagnostic strategies and will enable targeting of molecular therapies now in development. Older diagnostic methods that measure sweat chloride and nasal potential difference nonetheless remain important because of their sensitivity and specificity. In addition, the measurement of immunoreactive trypsinogen and the genotyping of CFTR alleles are key to newborn screening programs because of low cost. The multiorgan nature of cystic fibrosis leads to a heavy burden of care, thus therapeutic regimens are tailored to the specific manifestations present in each patient. The variability of cystic fibrosis lung disease and the variable expressivity of mild CFTR alleles complicate genetic counseling for this autosomal recessive disorder. Widespread implementation of newborn screening programs among populations with significant cystic fibrosis mutation carrier frequencies is expected to result in increasing demands on genetic counseling resources.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19092437      PMCID: PMC2810953          DOI: 10.1097/GIM.0b013e31818e55a2

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  111 in total

1.  Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population.

Authors:  X Wang; B Moylan; D A Leopold; J Kim; R C Rubenstein; A Togias; D Proud; P L Zeitlin; G R Cutting
Journal:  JAMA       Date:  2000-10-11       Impact factor: 56.272

2.  Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

Authors:  Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Margaret Rosenfeld; Ann Yunker; Nicole Hamblett; Frank Accurso; Mark Dovey; Peter Hiatt; Michael W Konstan; Richard Moss; George Retsch-Bogart; Jeffrey Wagener; David Waltz; Robert Wilmott; Pamela L Zeitlin; Bonnie Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2002-12-12       Impact factor: 21.405

Review 3.  Screening practices for mutations in the CFTR gene ABCC7.

Authors:  E Girodon-Boulandet; C Cazeneuve; M Goossens
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

4.  Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.

Authors:  J M Littlewood; M G Miller; A T Ghoneim; C H Ramsden
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

Review 5.  CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.

Authors:  A S Verkman; Gergely L Lukacs; Luis J V Galietta
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

6.  Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C.

Authors:  R J Massie; N Poplawski; B Wilcken; J Goldblatt; C Byrnes; C Robertson
Journal:  Eur Respir J       Date:  2001-06       Impact factor: 16.671

7.  Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis.

Authors:  P A de Jong; Y Nakano; M H Lequin; J R Mayo; R Woods; P D Paré; H A W M Tiddens
Journal:  Eur Respir J       Date:  2004-01       Impact factor: 16.671

8.  A mutation in CFTR produces different phenotypes depending on chromosomal background.

Authors:  S Kiesewetter; M Macek; C Davis; S M Curristin; C S Chu; C Graham; A E Shrimpton; S M Cashman; L C Tsui; J Mickle
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

9.  Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials.

Authors:  Thomas A Standaert; Louis Boitano; Julia Emerson; Laura J H Milgram; Michael W Konstan; Janice Hunter; Pierre-Yves Berclaz; Lois Brass; Pamela L Zeitlin; Keith Hammond; Zoe Davies; Carla Foy; Peadar G Noone; Michael R Knowles
Journal:  Pediatr Pulmonol       Date:  2004-05

10.  Standards and guidelines for CFTR mutation testing.

Authors:  Carolyn Sue Richards; Linda A Bradley; Jean Amos; Bernice Allitto; Wayne W Grody; Anne Maddalena; Matthew J McGinnis; Thomas W Prior; Bradley W Popovich; Michael S Watson; Glenn E Palomaki
Journal:  Genet Med       Date:  2002 Sep-Oct       Impact factor: 8.822

View more
  48 in total

Review 1.  The frontiers of sequencing in undiagnosed neurodevelopmental diseases.

Authors:  Hane Lee; Stanley F Nelson
Journal:  Curr Opin Genet Dev       Date:  2020-06-27       Impact factor: 5.578

2.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

3.  Cystic fibrosis carrier screening in Veneto (Italy): an ethical analysis.

Authors:  Tommaso Bruni; Matteo Mameli; Gabriella Pravettoni; Giovanni Boniolo
Journal:  Med Health Care Philos       Date:  2012-08

4.  Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Authors:  Samuel M Moskowitz; Elizabeth Garber; Yunhua Chen; Sarah A Clock; Setareh Tabibi; Amanda K Miller; Michael Doctor; Lisa Saiman
Journal:  J Antimicrob Chemother       Date:  2010-04-29       Impact factor: 5.790

5.  The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection.

Authors:  Samuel M Moskowitz; Robert K Ernst
Journal:  Subcell Biochem       Date:  2010

6.  Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants.

Authors:  Danieli Barino Salinas; Patrick R Sosnay; Colleen Azen; Suzanne Young; Karen S Raraigh; Thomas G Keens; Martin Kharrazi
Journal:  J Cyst Fibros       Date:  2015-03-29       Impact factor: 5.482

7.  Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency.

Authors:  R Sebro; H Levy; K Schneck; D Dimmock; B A Raby; C L Cannon; U Broeckel; N J Risch
Journal:  Clin Genet       Date:  2011-11-29       Impact factor: 4.438

Review 8.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

9.  Concerns about Genetic Testing for Schizophrenia among Young Adults at Clinical High Risk for Psychosis.

Authors:  Ryan E Lawrence; Phoebe Friesen; Gary Brucato; Ragy R Girgis; Lisa Dixon
Journal:  AJOB Empir Bioeth       Date:  2015-11-16

10.  The CFTR Met 470 allele is associated with lower birth rates in fertile men from a population isolate.

Authors:  Gülüm Kosova; Joseph K Pickrell; Joanna L Kelley; Patrick F McArdle; Alan R Shuldiner; Mark Abney; Carole Ober
Journal:  PLoS Genet       Date:  2010-06-03       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.